ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.85%
US Dollar vs MXN
16.98613
0.25%
Brent Oil
83.61
0.08%
Bitcoin
59,111.93
1.50%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Agile Therapeutics Inc (AGRX)

  7. Agile Therapeutics Inc (AGRX) Noticias

AGRX Agile Therapeutics Inc

0.6022
0.00 (0.00%)
Fuera de horario
Última actualización: 19:00:00
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Agile Therapeutics Inc AGRX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 0.6022 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.6022 0.6022
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
28/3/202407:05GLOBEAgile Therapeutics Reports Fourth Quarter & Full Year 2023..
25/3/202415:30GLOBEAgile Therapeutics Announces Delisting from Nasdaq
21/3/202405:35GLOBECorrection - Agile Therapeutics to Report Fourth Quarter and..
20/3/202407:15GLOBEAgile Therapeutics to Report Fourth Quarter and Full Year..
13/3/202406:31GLOBEAgile Therapeutics Completes Pay-off of Debt and Remains..
23/2/202415:57EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
23/2/202415:55EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
22/2/202408:01GLOBEAgile Therapeutics Announces Exercise of Warrants for $4.8..
15/2/202415:45EDGAR2Form 8-K - Current report
15/2/202415:30GLOBEAgile Therapeutics Announces Extension Granted by Nasdaq..
13/2/202419:02EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202415:51EDGAR2Form S-1/A - General form for registration of securities..
06/2/202409:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202408:21EDGAR2Form S-1/A - General form for registration of securities..
02/2/202415:27EDGAR2Form S-1/A - General form for registration of securities..
23/1/202408:29GLOBEThe Biden-Harris Administration Announces New Guidance to..
20/12/202307:00EDGAR2Form S-1/A - General form for registration of securities..
12/12/202307:01GLOBEAgile Therapeutics Provides Update on Actions Being Taken to..
11/12/202316:30EDGAR2Form S-1 - General form for registration of securities under..
06/12/202307:00EDGAR2Form 8-K - Current report
04/12/202307:00EDGAR2Form 8-K - Current report
09/11/202315:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202307:15EDGAR2Form 8-K - Current report
09/11/202307:05GLOBEAgile Therapeutics Reports Third Quarter 2023 Financial..
26/10/202307:05GLOBEAgile Therapeutics to Report Third Quarter 2023 Financial..
04/10/202315:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202315:30GLOBEAgile Therapeutics Reports an Inducement Grant to New Chief..
02/10/202315:30EDGAR2Form 8-K - Current report
28/9/202315:50EDGAR2Form 8-K - Current report
05/9/202307:05GLOBEAgile Therapeutics to Present at the H.C. Wainwright 25th..
25/8/202315:02EDGAR2Form 3 - Initial statement of beneficial ownership of..
22/8/202307:30EDGAR2Form 8-K/A - Current report: [Amend]
09/8/202315:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202307:10EDGAR2Form 8-K - Current report
09/8/202307:05GLOBEAgile Therapeutics Reports Second Quarter 2023 Financial..
26/7/202307:30GLOBEAgile Therapeutics to Report Second Quarter 2023 Financial..
30/6/202315:50EDGAR2Form 8-K - Current report
30/6/202315:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/6/202315:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/6/202315:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/6/202315:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/6/202315:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/6/202307:01GLOBEAgile Therapeutics Announces the Availability of Twirla® to..
23/6/202311:05GLOBEAgile Therapeutics Commends the Biden Administration’s..
15/6/202315:05GLOBEAgile Therapeutics Announces the Availability of Twirla®..
13/6/202315:05GLOBEAgile Therapeutics Announces New Agreement with vitaCare®..
25/5/202315:05GLOBEAgile Therapeutics Announces Closing of $7.5 Million Public..
22/5/202319:00GLOBEAgile Therapeutics Announces Pricing of $7.5 Million Public..
11/5/202315:05GLOBEAgile Therapeutics Reports First Quarter 2023 Financial..
08/5/202307:00GLOBEAgile Therapeutics to Report First Quarter 2023 Financial..

Su Consulta Reciente

NASDAQ
AGRX
Agile Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados